Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer

NCT00082810 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

33

Enrollment

NIH

Sponsor class

Conditions

Estrogen Receptor-positive Breast Cancer
Recurrent Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions

DRUG: fulvestrant
DRUG: tipifarnib

Sponsor

National Cancer Institute (NCI)